Arafa N et al. Changing pattern of hepatitis C virus spread in rural areas of Egypt. J Hepatol. 43(3):418-24, 2005.
Aslam M et al. Association between smallpox vaccination and hepatitis C antibody positive serology in Pakistani volunteers. J Clin Gastroenterol. 39(3):243-6, 2005.
Backus LI et al. Effects of hepatitis C virus coinfection on survival in veterans with HIV treated with highly active antiretroviral therapy. J Acquir Immune Defic Syndr 39: 613-619, 2005.
Bonacini M et al. Survival in patients with HIV infection and viral hepatitis B or C: a cohort study. AIDS 18: 2039-2045, 2004.
Browne R et al. What is your patient taking? Dietary supplements in a HIV-positive patient. International Journal of STD and AIDS 16: 639 – 641, 2005.
Burnett RJ et al. Hepatitis B virus and human immunodeficiency virus co-infection in sub-Saharan Africa: a call for further investigation. Liver International 25: 201-213, 2005.
Deuffic-Burban S et al Expected increase in hepatitis C-related mortality in Egypt due to pre-2000 infections. J Hepatol. 2005.
Drake A et al. Immune reconstitution hepatitis in HIV and hepatitis B coinfection, despite lamivudine therapy as part of HAART. Clin Infect Dis 39, 2004.
Khaja MN et al. High prevalence of hepatitis C virus infection and genotype distribution among general population, blood donors and risk groups. Infect Genet Evol. 2005.
Klein MB et al. The impact of hepatitis C virus coinfection on HIV progression before and after highly active antiretroviral therapy. J Acquir Immune Defic Syndr 33: 365-372, 2003.
Kumarasamy, N et al. Reasons for modification of generic highly active antiretroviral therapeutic regimens among patients in southern India. JAIDS Journal of Acquired Immune Deficiency Syndromes. 41(1):53-58, 2006.
Lumbreras B et al. Impact of hepatitis C infection on long-term mortality of injecting drug users from 1990 to 2002: differences before and after HAART. AIDS 20: 111 – 116, 2006.
Madhava V, Burgess C, Drucker E. Epidemiology of chronic hepatitis infection in sub-Saharan Africa.
Lancet Infect Dis; 2: 293–302, 2002.
Mocroft A et al. Is there evidence for an increase in the death rate from liver-related disease in patients with HIV? AIDS 19: 2117 – 2125, 2005.
National Institutes of Health. Management of Hepatitis C: 2002. NIH Consensus and State-of-the-Science Statements. 19(3), 2002.
Paris R et al. The association between hepatitis C virus and HIV-1 in preparatory cohorts for HIV vaccine trials in Thailand. AIDS 17(9):1363-7, 2003.
Ratnam I et al. Incidence and risk factors for immune reconstitution inflammatory syndrome in an ethnically diverse HIV type-1-infected cohort. Clinical Infectious Diseases 42: 418-427, 2006
Rhodes T et al. Hepatitis C virus infection, HIV co-infection, and associated risk among injecting drug users in Togliatti, Russia. Int J STD AIDS. 16(11):749-54 2005.
Sherman KE et al. Liver injury and changes in hepatitis C virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients: lopinavir-ritonavir versus nelfinavir. Clin Inf Dis 41: 000-000, 2005.
Sunkanuparph S et al. Prevalence of hepatitis B virus and hepatitis C virus co-infection with human immunodeficiency virus in Thai patients: a tertiary-care-based study.J Med Assoc Thai 87(11):1349-54, 2004.
Verma S et al. Do type and duration of antiretroviral therapy attenuate liver fibrosis in HIV-hepatitis C virus-coinfected patients? Clin Infect Dis 42: XXX-XXX, 2006.
Zhang L et al. Molecular Characterization of Human Immunodeficiency Virus Type 1 and Hepatitis C Virus in Paid Blood Donors and Injection Drug Users in China. J Virol. 78(24): 13591–13599 2004.